


## Sarpogrelate-d3 hydrochloride

<b>Cat. No.:</b>	HY-10564S
<b>Molecular Formula:</b>	C <sub>24</sub> H <sub>29</sub> D <sub>3</sub> ClNO <sub>6</sub>
<b>Molecular Weight:</b>	468.99
<b>Target:</b>	5-HT Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Sarpogrelate-d3 hydrochloride (MCI-9042-d3) is the deuterium labeled Sarpogrelate hydrochloride. Sarpogrelate hydrochloride (MCI-9042) is a selective 5-HT <sub>2</sub> R antagonist, with pK <sub>s</sub> of 8.52, 6.57, and 7.43 for 5-HT <sub>2A</sub> , 5-HT <sub>2B</sub> , and 5-HT <sub>2C</sub> receptors, respectively. Sarpogrelate hydrochloride displays selectivity over 5-HT <sub>1</sub> , 5-HT <sub>3</sub> , 5-HT <sub>4</sub> , α <sub>1</sub> -, α <sub>2</sub> - and β-adrenoreceptor, histamine H <sub>1</sub> , H <sub>2</sub> and muscarinic M <sub>3</sub> receptors. Sarpogrelate hydrochloride can be used for the research of vascular disease associated with thrombosis <sup>[1][2][3]</sup> .
<b>In Vitro</b>	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Rashid M, et, al. Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT<sub>2</sub> antagonist, to human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptor subtypes by molecular modeling. *Life Sci.* 2003 May 30;73(2):193-207.
- [3]. Maruyama K, et, al. MCI-9042: high affinity for serotonergic receptors as assessed by radioligand binding assay. *J Pharmacobiodyn.* 1991 Apr;14(4):177-81.
- [4]. Kataoka H, et, al. Inhibitory Effect of Serotonin Antagonist on Leukocyte-Endothelial Interactions In Vivo and In Vitro. *PLoS One.* 2016 Jan 29;11(1):e0147929.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA